Blar i Publikasjoner fra Cristin - St. Olavs hospital på forfatter "Aas, Kirsti"

Viser treff 1-3 av 3

    • Definitive radiotherapy for prostate cancer in Norway 2006-2015: Temporal trends, performance and survival 

      Fosså, Sophie Dorothea; Aas, Kirsti; Muller, Christoph Rainer; Jerm, Marianne Brenn; Tandstad, Torgrim; Lilleby, Wolfgang; Kvåle, Rune; Gulbrandsen, Johanne; Haug, Erik Skaaheim; Myklebust, Tor Åge (Peer reviewed; Journal article, 2020)
      Background: More studies are needed to document nation-wide use and effectiveness of curative definitive radiotherapy (Def-RT) in the treatment of prostate cancer (PCa). Patients and methods: For 38,960 men diagnosed with ...

    • Impact of prebiopsy MRI on prostate cancer staging: Results from the Norwegian Prostate Cancer Registry 

      Haug, Erik Skaaheim; Myklebust, Tor Åge; Juliebø-Jones, Patrick; Reisæter, Lars Anders Rokne; Aas, Kirsti; Berg, Arne Stenrud; Muller, Christoph Rainer; Hofmann, Bjørn Morten; Størkersen, Øystein; Nilsen, Kim L.; Johannessen, Tom Børge; Beisland, Christian (Peer reviewed; Journal article, 2023)
      The aim of this study is to evaluate the 2015 introduction of prebiopsy magnetic resonance imaging of the prostate (MRI-P) as the standard of care for diagnosing prostate cancer (PCa) by the Norwegian public health care ...

    • Protocol of a randomised, controlled trial comparing immediate curative therapy with conservative treatment in men aged ≥75 years with non-metastatic high-risk prostate cancer (SPCG 19/GRand-P) 

      Löffeler, Sven; Bertilsson, Helena Maria; Müller, Christoph Rainer; Aas, Kirsti; Haugnes, Hege Sagstuen; Aksnessæther, Bjørg Yksnøy; Pesonen, Maiju; Thon, Kristian; Tandstad, Torgrim; Murtola, Teemu; Poulsen, Mads Hvid Aaberg; Nordstrøm, Tobias; Vigmostad, Maria Nyre; Ottosson, Fredrik; Holmsten, Karin; Christiansen, Ola B.; Slaaen, Marit; Haug, Erik Skaaheim; Storås, Anne Holck; Asphaug, Lars; Rannikko, Antti; Brasso, Klaus (Peer reviewed; Journal article, 2024)
      Background Older men (aged ≥75 years) with high risk, non-metastatic prostate cancer (PCa) are increasingly treated with curative therapy (surgery or radiotherapy). However, it is unclear if curative therapy prolongs ...